Daily Sepsis Research Analysis
Analyzed 35 papers and selected 3 impactful papers.
Summary
Three studies advanced sepsis risk stratification and diagnosis. A large database study introduced a sepsis-specific systemic inflammation classification (SSIC) combining NLR and GLR to improve mortality prediction and augment existing severity scores. Complementary work showed the lactate-to-PaO2 ratio (LPR) outperforms lactate alone for 28-day mortality, and a rapid host-response gene expression assay (SeptiScore) distinguished healthcare-associated infection from trauma-related SIRS in ICU patients.
Research Themes
- Bedside risk stratification with routine laboratory indices
- Rapid host-response diagnostics for infection versus sterile inflammation
- Augmenting established severity scores using EHR-scale validation
Selected Articles
1. Development and validation of a sepsis-specific systemic inflammation classification system for mortality prediction.
Using 11,577 ICU sepsis cases from MIMIC-IV, seven of 18 nutrition/inflammation indices predicted mortality, with NLR and GLR performing best. A new SSIC combining NLR and GLR stratified inflammation into low/moderate/high and improved mortality discrimination, adding value to established severity scores; findings were validated in an external 496-patient cohort.
Impact: Introduces a simple, sepsis-specific classification that leverages readily available labs to augment risk prediction and existing severity scores. The large development cohort and independent validation support generalizability.
Clinical Implications: SSIC could be integrated into ICU workflows to rapidly stratify mortality risk and to refine decisions about monitoring intensity, escalation, and trial enrollment alongside SOFA/SAPS II.
Key Findings
- Among 18 indices, NLR and GLR showed the strongest mortality prediction in sepsis.
- Combining NLR and GLR into the SSIC (low/moderate/high) improved discrimination for in-hospital and ICU mortality.
- Adding SSIC to established severity scores further enhanced mortality prediction.
- External validation in 496 patients confirmed consistent performance across subpopulations.
Methodological Strengths
- Large development cohort (n=11,577) with comparison across 18 indices
- Independent external validation and assessment of incremental value over severity scores
Limitations
- Retrospective design with potential residual confounding and selection bias
- External validation cohort was relatively small and single-institutional
Future Directions: Prospective, multicenter evaluation; dynamic (serial) assessment of SSIC; integration into clinical decision support to test impact on outcomes.
BACKGROUND: The role of nutrition and systemic inflammation in the prognosis of sepsis remains unclear. This study aimed to evaluate the predictive value of existing nutrition/inflammation-based indices for mortality in sepsis patients and to develop a sepsis-specific systemic inflammation classification (SSIC) system. METHODS: Using the MIMIC-IV 3.0 database, we investigated and compared the predictive value of 18 nutrition/inflammation-based indices for mortality in sepsis patients admitted to the intensive care unit (ICU). These indices were calculated from biochemical tests and anthropometric measurements at ICU admission. The SSIC system was established by combining existing indices and validated in an independent institutional cohort. RESULTS: Analysis of 11,577 sepsis patients from the MIMIC-IV 3.0 database revealed that seven of the 18 nutrition/inflammation-based indices had predictive value for in-hospital and in-ICU mortality, albeit with low discriminative ability. The neutrophil-to-lymphocyte ratio (NLR) and glucose-to-lymphocyte ratio (GLR), both of which focus on systemic inflammation, demonstrated the best predictive performance in both indirect and direct comparisons. The SSIC system, which combines NLR and GLR, classified systemic inflammation risk into low, moderate, and high categories. This system improved discriminative ability for mortality and showed consistent predictive value across different subpopulations. Moreover, adding the SSIC system to existing severity scores enhanced their discriminative performance for sepsis mortality. The utility of the SSIC system was validated in an independent institutional cohort of 496 sepsis patients. CONCLUSION: This study confirmed the predictive value of 18 nutrition/inflammation-based indices for mortality in sepsis patients. The SSIC system was established and validated as a tool for mortality risk stratification and may be considered for further evaluation alongside established severity scores.
2. Association of lactate to Po2 ratio (LPR) with 28-day mortality in ICU sepsis: A retrospective cohort study based on the MIMIC-IV database.
In 14,921 ICU sepsis patients, the lactate-to-PaO2 ratio (LPR) achieved an AUC of 0.725 for 28-day mortality, comparable to OASIS and SAPS II and superior to SOFA. LPR remained independently associated with mortality after adjusting for lactate and severity scores, and it improved risk reclassification beyond SOFA, SAPS II, and OASIS.
Impact: LPR combines two widely available parameters into a single index with robust, generalizable prognostic value and incremental utility over established scores.
Clinical Implications: Early LPR calculation may enhance bedside risk stratification and guide escalation, monitoring intensity, and goals-of-care discussions alongside standard severity scoring.
Key Findings
- LPR predicted 28-day mortality with AUC 0.725, comparable to OASIS and SAPS II and superior to SOFA.
- An LPR cutoff of 0.137 stratified survival on Kaplan–Meier analysis (P<0.001).
- LPR10 independently associated with mortality (OR 1.61) after adjustment, and improved NRI over SOFA, SAPS II, and OASIS.
- No significant interactions across clinical subgroups, supporting broad applicability.
Methodological Strengths
- Very large single-institution database cohort with comprehensive statistical framework (ROC, K-M, multivariable, NRI)
- Demonstrated incremental prognostic value beyond established severity scores
Limitations
- Retrospective, single-institution dataset with potential residual confounding and selection bias
- Timing/standardization of arterial gases and lactate may vary; external validation not shown
Future Directions: Prospective multicenter validation; assessment of dynamic LPR trajectories; integration into clinical decision support and sepsis bundles.
The high mortality rate among patients with sepsis continues to be a major hurdle in critical care environments, and metabolic imbalances are a defining feature of the underlying pathophysiology of this disease. However, the association between the lactate-to-oxygen tension ratio (LPR) and patient outcomes in sepsis remains underexplored, with insufficient research to fully elucidate its clinical significance. In the context of assessing a patient's metabolic health, lactate alone might not be sufficient to fully capture their physiological condition, as it is influenced by non-hypoxic factors including hepatic dysfunction, catecholamine administration, and renal clearance impairment. The integration of lactate and arterial partial pressure of oxygen (PaO2) into the LPR offers a composite measure that simultaneously reflects tissue metabolic stress and systemic oxygenation status, potentially providing a more comprehensive representation of the metabolic-oxygenation mismatch characteristic of sepsis. This research examines the relationship between LPR and 28-day mortality rates among patients with sepsis admitted to the intensive care unit. According to ICD-9 diagnosis codes, patients diagnosed with sepsis in the Medical Information Mart for Intensive Care IV (v.2.2) database were selected. The receiver operating characteristic (ROC) curve, Kaplan-Meier (K-M) survival curve, logistic regression analyses, sensitivity analysis, and subgroup analysis were used to assess the predictive power of LPR. Based on the MIMIC-IV database, patients with sepsis admitted to the ICU for the first time (n = 14,921) were included. The 28-day mortality was 17.26%. The area under the ROC curve (AUC) for LPR was 0.725 (95% confidence interval [CI], 0.714-0.73), which was comparable to that of OASIS (0.765; 95% CI, 0.755-0.775) and SAPSII (0.772; 95% CI, 0.762-0.781), and superior to SOFA (0.624; 95% CI, 0.612-0.636; P = .500). The cutoff value of LPR was 0.137 based on the ROC curve. The high LPR group showed a poor prognosis in the K-M analysis (P < .001). Multivariate logistic regression showed that LPR10 was significantly associated with poor outcome (odds ratio, 1.61; 95% CI, 1.42-1.84; P < .001), after adjusting for lactate alone and established severity scores. Net Reclassification Improvement analyses confirmed incremental prognostic value of LPR beyond SOFA (NRI 0.142; P < .001), SAPS II (NRI 0.118; P < .001), and OASIS (NRI 0.095; P < .001). Subgroup analysis showed no significant interaction between LPR and any subgroup (P for interaction: 0.065-0.867). LPR is a rational and easily accessible marker that is strongly associated with 28-day mortality in ICU patients with sepsis. The integration of lactate and PaO2 into a single ratio captures prognostic information beyond that provided by either parameter alone or by established severity scores, offering a practical bedside tool for early risk stratification.
3. Clinical evaluation of the SeptiScore biomarker for the diagnosis of healthcare-associated infections in critically ill trauma patients: a multicenter derivation and validation cohort study.
In ICU trauma patients with SIRS and hemodynamic failure, SeptiScore measured at suspicion of infection distinguished HCAI from trauma-related SIRS (derivation AUC 0.79; threshold 6.7: sensitivity 0.84, specificity 0.66, LR− 0.24), outperforming CRP, PCT, and leukocyte count. Performance was consistent in a small independent validation cohort.
Impact: Demonstrates rapid, host-response gene expression testing can improve infection diagnosis where sterile inflammation confounds clinical assessment, with bedside turnaround suitable for time-critical ICU decisions.
Clinical Implications: A pre-specified SeptiScore threshold may support early antimicrobial decisions and stewardship (rule-out via low LR−), reducing diagnostic uncertainty in trauma ICUs.
Key Findings
- SeptiScore was significantly higher in HCAIs than in trauma-related SIRS and remained independently associated with infection status (p<0.001).
- Derivation AUC 0.79; threshold 6.7 achieved sensitivity 0.84, specificity 0.66, and LR− 0.24, outperforming CRP, PCT, and leukocyte count.
- Pre-specified threshold showed consistent performance in a small independent validation cohort (AUC 0.98).
Methodological Strengths
- Prospective derivation with pre-specified threshold and independent validation
- Appropriate modeling for repeated measures (mixed-effects) and cluster bootstrap CIs; biomarker head-to-head comparisons
Limitations
- Small sample size and limited events in validation, yielding imprecise estimates
- Restricted to trauma ICU with SIRS and hemodynamic failure; generalizability uncertain
Future Directions: Larger multicenter prospective validation; evaluation of clinical impact on antimicrobial stewardship, imaging, and length of stay.
BACKGROUND: Diagnosing healthcare-associated infections (HCAIs) in critically ill trauma patients is difficult, because trauma-related non-septic systemic inflammatory response syndrome (SIRS) closely mimics infection and conventional biomarkers lack specificity. SeptiCyte RAPID is a fully automated host-response assay that quantifies the expression of two genes and returns a SeptiScore within one hour, making it suitable for bedside use. Our primary objective was to determine an optimal SeptiScore threshold for identifying HCAIs in a derivation cohort and to evaluate it in an independent validation cohort; secondary objectives were to assess diagnostic performance and to compare SeptiScore with conventional biomarkers. METHODS: This two-center diagnostic study included a prospective derivation cohort (82 samples, 44 patients) and a retrospective validation cohort (31 samples, 31 patients), comprising adult ICU trauma patients with SIRS and hemodynamic failure. SeptiScore was measured at clinical suspicion, before microbiological confirmation. Because some patients contributed several samples, the association between SeptiScore and infection was analyzed using linear mixed-effects models with a random patient intercept, and confidence intervals for diagnostic metrics were estimated using a patient-level cluster bootstrap. Diagnostic accuracy was assessed by ROC curves, the Youden index, and negative likelihood ratios (LR -), and compared with C-reactive protein, procalcitonin, and leukocyte count. RESULTS: Overall, 113 samples (71 trauma-related SIRS, 42 HCAIs) were analyzed. SeptiScore was higher in HCAIs (median 8.05, IQR 6.83-8.80) than in trauma-related SIRS (5.80, 5.08-7.05), and infection status remained independently associated with SeptiScore after accounting for within-patient correlation (p < 0.001). In the derivation cohort, the area under the ROC curve was 0.79 (95% CI 0.72-0.87). A threshold of 6.7 yielded sensitivity 0.84 (0.72-0.97), specificity 0.66 (0.53-0.79), and LR - 0.24 (0.04-0.53), outperforming conventional biomarkers. In the smaller validation cohort, the pre-specified threshold showed consistent performance (AUC 0.98; 95% CI 0.94-1.00), although these estimates are imprecise given the limited number of events. CONCLUSIONS: SeptiScore showed promising performance for distinguishing HCAIs from trauma-related SIRS and outperformed conventional biomarkers. These hypothesis-generating findings require confirmation in larger, adequately powered multicenter studies before clinical use.